Evaluation of Hematological Parameters in Predicting Short-Term Mortality for COVID 19 Patients with Gastrointestinal Symptoms: A Case-Control Study

Yıl 2021, Cilt: 11 Sayı: 5, 710 - 714, 17.09.2021

Serdar Özdemir , Abdullah Algın

https://doi.org/10.16899/jcm.972664

Cited By: 2

Öz

Introduction: Due to local and systemic pathological mechanisms, the laboratory parameters -especially hematological parameters of patients with gastrointestinal symptoms may differ from those without. We aimed to investigate the difference between the hematological parameters of COVID 19 patients with gastrointestinal symptoms and those without.
Material and methods: Our study was designed as a retrospective case-control study. The case group consisted of COVID 19 patients with confirmed gastrointestinal symptoms. The control group consisted of COVID 19 patients without gastrointestinal symptoms. The hematological parameters of the patients were compared statistically.
Results: One hundred and thirty patients were included in the case group, and 130 patients were included in control group. There was no statistical difference between the groups in terms of white blood cell count, neutrophil count, lymphocyte count, platelet count, hemoglobin, hematocrit, mean platelet volume, mean corpuscular volume, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio (p values: 0.642, 0.987, 0.132, 0.835, 0.306, 0.430, 0.057, 0.735, 0.321, 0.031, respectively)
Conclusion: There is no significant difference between the COVID 19 patients with gastrointestinal symptoms and those without in the terms of the hematological parameters.

Anahtar Kelimeler

case- control study, COVID-19, gastrointestinal symptoms, mortality, SARS-CoV-2

Kaynakça

• 1. Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020;12(3):e7423. doi:10.7759/cureus.7423
• 2. Eroglu SE, Aksel G, Altunok I, et al. Can Google® trends predict emergency department admissions in pandemic periods? Medicine Science 2021;10(1):111-7.
• 3. Sert E, Mutlu H, Kokulu K, Sarıtaş A. Anxiety Levels and Associated Factors Among Emergency Department Personnel Fighting COVID-19. J Contemp Med. 2020; 10(4): 556-561.
• 4. Galanopoulos M, Gkeros F, Doukatas A, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020;26(31):4579-4588. doi:10.3748/wjg.v26.i31.4579
• 5. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382: 929–36.
• 6. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708-20
• 7. Song Y, Liu P, Shi XL, et al. SARS-CoV-2 induced diarrhea as onset symptom in patient with COVID-19. Gut. 2020; 69(6): 1143-4.
• 8. Chen L, Luo JH, Bai Y, Wang M. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. Am J Gastroenterol. 2020; 115(5): 790
• 9. Lee C, Huo T, Huang Y. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020; 83(6): 521-3.
• 10. Liang W, Feng Z, Rao S, et al. Diarrhea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020; 69(6): 1141-3.
• 11. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271-80.
• 12. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7): e00127–20.
• 13. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055
• 14. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50-54. doi:10.1126/science.abc1669
• 15. Guo M, Tao W, Flavell RA, Zhu S. Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283. doi: 10.1038/s41575-021-00416-6.
• 16. Cao TT, Zhang GQ, Pellegrini E, et al. COVID-19 and its effects on the digestive system. World J Gastroenterol. 2021 Jun 28;27(24):3502-3515. doi: 10.3748/wjg.v27.i24.3502.
• 17. Zuo T, Liu Q, Zhang F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021 Feb;70(2):276-284. doi: 10.1136/gutjnl-2020-322294.